MAP2K7 and hepatocellular carcinoma: Breunig et al., in a preclinical study, compared sorafenib with the MEK-inhibitors AZD6244 and PD0325901, and the BRAFV600E mutation-specific inhibitor PLX4720 in HCC cell lines regarding the inhibition of MAPK and PI3K to point out a difference of activity in cell proliferation, viability, apoptosis, and chemokine/growth factor secretion [39].